# Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

> **NCT00246753** · PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** lapatinib ditosylate

## Key facts

- **NCT ID:** NCT00246753
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2012-07
- **Final completion:** 2013-05
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2017-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00246753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00246753, "Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00246753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*